J Korean Soc Plast Reconstr Surg.  1998 Apr;25(3):446-452.

A clinical review of eyelid sebaceous carcinoma

Affiliations
  • 1Department of Plastic Surgery, The Catholic University of Korea, College of Medicine, Seoul, Korea.

Abstract

Malignant tumors of the eyelid pose a serious threat because of their proximity to the globe, brain & paranasal sinuses. Three types of carcinomas account for the vast majority of the malignant eyelid tumors: basal cell carcinoma, squamous cell carcinoma, and sebaceous gland carcinoma. In these malignancies, basal cell carcinoma is the most common. However, sebaceous gland carcinoma has a high recurrence rate and a moderately high 5-year mortality rate because of late diagnosis and incomplete surgical removal. This tumor may be clinically misdiagnosed frequently as a chronic unilateral conjunctivitis, chalazion, basal cell carcinoma, or squamous cell carcinoma in initial biopsy. Suspicious lid lesions should be managed with incisional biopsy initially. If they are positive for sebaceous gland carcinoma, wide excision and frozen section monitoring of surgical margin is the treatment of choice. The final diagnosis should be confirmed by special stain for lipid. We experienced 12 cases of malignant eyelid tumors including 3 cases of sebaceous gland carcinoma. In cases of sebaceous gland carcinoma, wide surgical excision with frozen section monitoring was performed and followed by eyelid reconstruction with intact eyelid tissue remained and adjuvant radiotheraphy. Guidelines for management are discussed.

Keyword

Malignant eyelid tumor; Sebaceous gland carcinoma

MeSH Terms

Biopsy
Brain
Carcinoma, Basal Cell
Carcinoma, Squamous Cell
Chalazion
Conjunctivitis
Delayed Diagnosis
Diagnosis
Eyelids*
Frozen Sections
Mortality
Paranasal Sinuses
Recurrence
Sebaceous Glands
Full Text Links
  • JKSPRS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr